Hide metadata

dc.date.accessioned2019-04-05T09:04:05Z
dc.date.available2019-04-05T09:04:05Z
dc.date.created2018-01-11T09:06:10Z
dc.date.issued2018
dc.identifier.citationAbedini, Sadollah Gøransson, Lasse Cockburn, Elinor Kilany, Suzanne Holdaas, Hallvard . Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. Transplantation direct. 2018, 4(2), 1-7
dc.identifier.urihttp://hdl.handle.net/10852/67579
dc.description.abstractBackground. This study investigated medication adherence in kidney transplant patients (KTPs) converted from immediaterelease tacrolimus (IR-T) to prolonged-release tacrolimus (PR-T)-based immunosuppression in routine practice. Methods. Noninterventional, observational, multicenter study in Norway. Included adult KTPs with stable graft function, converted from IR-T (baseline) to PR-T (1 mg:1 mg) in routine practice. Data were collected at baseline, and months 1, 3, 6, and 12 postconversion. Primary endpoint: adherence using the Basel Assessment of Adherence to Immunosuppressive Medication Scale. Secondary assessments: tacrolimus dose and trough levels (target, 3-7 ng/mL), clinical laboratory parameters (eg, estimated glomerular filtration rate [Modified Diet in Renal Disease]), and adverse events. Results. Ninety-one KTPs (mean ± SD age 47.7 ± 14.3 years) were analyzed. Mean ± SD change in PR-T dose from baseline (4.4 ± 2.4 mg/d) to month 12 was −0.1 ± 0.9 mg/d; mean tacrolimus trough levels remained within target. Overall medication adherence increased from 45.6% at baseline to 58.1% at month 1, but was similar to baseline thereafter; taking and timing adherence followed a similar pattern. Odds ratio (OR) for adherence at month 1 (but not at other time points) was greater versus baseline for overall (OR, 1.71; P = 0.0205), taking (OR, 3.38; P = 0.0004), and timing (OR, 1.77, P = 0.0252) dimensions. Mean ± SD Basel Assessment of Adherence to Immunosuppressive Medication Scale visual analogue scale score at baseline was 96.4 ± 5.5%, and increased postconversion. Estimated glomerular filtration rate remained stable (month 12, 61.6 ± 17.7 mL/min per 1.73 m2 ), as did other laboratory parameters. Two (2.2%) patients had adverse events considered probably/possibly treatment-related. Conclusions. There was disparity between high, patient-perceived and low, actual adherence. Converting stable KTPs from IR-T to PR-T in routine practice did not impact longterm adherence to immunosuppression; renal function remained stable.en_US
dc.languageEN
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleImmunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Studyen_US
dc.typeJournal articleen_US
dc.creator.authorAbedini, Sadollah
dc.creator.authorGøransson, Lasse
dc.creator.authorCockburn, Elinor
dc.creator.authorKilany, Suzanne
dc.creator.authorHoldaas, Hallvard
cristin.unitcode185,53,48,12
cristin.unitnameAvdeling for transplantasjonsmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1540439
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Transplantation direct&rft.volume=4&rft.spage=1&rft.date=2018
dc.identifier.jtitleTransplantation direct
dc.identifier.volume4
dc.identifier.issue2
dc.identifier.startpage1
dc.identifier.endpage7
dc.identifier.doihttp://dx.doi.org/10.1097/TXD.0000000000000755
dc.identifier.urnURN:NBN:no-70749
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn2373-8731
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/67579/2/Immunosuppression%2BAdherence%2Bin%2BStable%2BKidney.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International